Genmab — August 2016
-
Apropos vores Q&A. Jeg har mange spørgsmål, men flertallet handler om det samme. Please..Please. Spørg nu løs så vi får dern sædvanlige brede flade belyst.
-
-
Der er spurgt rigtig meget til tidspunkt for indsendelse af ansøgning for 2. linje og Darzalex i faste tumorer. Vi savner de sædvanlige spørgsmål om udviklingen i klinikken.
-
Hi Helge, I am new here and see that you want questions. What I would like to know is what is the status with Gilead. They apearred omn a slide in January but I haven't heard anything important after that. I believe they have been snooping around for at least a year and a half right now.
-
Thank pcf. I will ask about it on your behalf.
-
Se eventuelt vores seneste Q&A. Der er flere spørgsmål som fortjener en opfølgning.
-
Artikel om dagens regnskab fra business: http://www.business.dk/medico/genmab-opjusterer-guldaeg-saelger-bedre-end-ventet
-
front line recruitment (Alcyon) completed
-
arzerra subcu indrulleing starter september
-
hele omkostningsstigningen går til r&d expenses - G&A får kun 2 mio ekstra. Me likes!
-
net financial giver 1 mio skæve - de burde investere i GEN aktier i stedet!!!
-
hexabody dr5 - vidste vi at det var target?
-
Tak for opdatering dingle.
-
omk increase kommer primært fra acceleration af duobody cd20/cd3 mod klinikken
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind